First Merchants Corp Has $773,000 Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

First Merchants Corp decreased its stake in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 85.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,445 shares of the medical research company's stock after selling 60,491 shares during the period. First Merchants Corp's holdings in Edwards Lifesciences were worth $773,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Alpha Financial Partners LLC acquired a new stake in Edwards Lifesciences during the third quarter worth $693,000. Trust Co. of Vermont boosted its stake in Edwards Lifesciences by 36.1% during the third quarter. Trust Co. of Vermont now owns 3,019 shares of the medical research company's stock worth $199,000 after buying an additional 801 shares in the last quarter. V Square Quantitative Management LLC boosted its stake in Edwards Lifesciences by 10.6% during the third quarter. V Square Quantitative Management LLC now owns 15,026 shares of the medical research company's stock worth $992,000 after buying an additional 1,437 shares in the last quarter. Aaron Wealth Advisors LLC acquired a new stake in Edwards Lifesciences during the third quarter worth $273,000. Finally, Net Worth Advisory Group acquired a new stake in Edwards Lifesciences during the third quarter worth $437,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Trading Down 0.7 %

NYSE:EW traded down $0.52 on Tuesday, hitting $75.67. 4,889,874 shares of the stock were exchanged, compared to its average volume of 4,515,657. The stock has a market capitalization of $44.63 billion, a price-to-earnings ratio of 10.92, a P/E/G ratio of 3.64 and a beta of 1.10. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company's 50-day moving average price is $72.78 and its 200 day moving average price is $69.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 500 shares of the business's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the completion of the transaction, the director now owns 60,372 shares of the company's stock, valued at $4,613,628.24. This represents a 8.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 26,489 shares of company stock worth $2,002,829. 1.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Citigroup lifted their price target on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Truist Financial restated a "hold" rating and issued a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Canaccord Genuity Group boosted their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research note on Thursday, February 13th. Finally, Daiwa America downgraded shares of Edwards Lifesciences from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.